دورية أكاديمية
أعرض في EDS

Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.

التفاصيل البيبلوغرافية
العنوان: Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.
المؤلفون: Powers JM; Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX; Department of Pediatrics, Baylor College of Medicine, Houston, TX; Texas Children's Hospital, Houston, TX. Electronic address: Jacquelyn.Powers@bcm.edu., Shamoun M; Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX; Children's Health, Dallas, TX., McCavit TL; Division of Hematology/Oncology, Cook Children's Hospital, Fort Worth, TX; Department of Pediatrics, Cook Children's Hospital, Fort Worth, TX., Adix L; Children's Health, Dallas, TX., Buchanan GR; Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX; Children's Health, Dallas, TX; Division of Hematology/Oncology, The University of Texas Southwestern Medical Center, Dallas, TX.
المصدر: The Journal of pediatrics [J Pediatr] 2017 Jan; Vol. 180, pp. 212-216. Date of Electronic Publication: 2016 Oct 21.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 0375410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6833 (Electronic) Linking ISSN: 00223476 NLM ISO Abbreviation: J Pediatr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: St. Louis, MO : Mosby
مواضيع طبية MeSH: Anemia, Iron-Deficiency/*drug therapy , Ferric Compounds/*administration & dosage , Maltose/*analogs & derivatives, Administration, Oral ; Adolescent ; Child ; Child, Preschool ; Cohort Studies ; Female ; Humans ; Infant ; Infusions, Intravenous ; Iron/administration & dosage ; Male ; Maltose/administration & dosage ; Retrospective Studies ; Treatment Outcome
مستخلص: Objective: To assess the benefits and risks of intravenous (IV) ferric carboxymaltose (FCM) in children with iron deficiency anemia (IDA).
Study Design: In a retrospective cohort study of patients seen at our center, we identified all FCM infusions in children with IDA over a 12-month period through a query of pharmacy records. Clinical data, including hematologic response and adverse effects, were extracted from the electronic medical record.
Results: A total of 116 IV FCM infusions were administered to 72 patients with IDA refractory to oral iron treatment (median age, 13.7 years; range, 9 months to 18 years). Median preinfusion and postinfusion hemoglobin values were 9.1 g/dL and 12.3 g/dL, respectively (at 4-12 weeks after the initial infusion; n = 53). Sixty-five patients (84%) experienced no adverse effects. Minor transient complications were encountered during or immediately after 7 infusions.
Conclusion: FCM administered as a short IV infusion without a test dose proved to be safe and highly effective in a small yet diverse population of infants, children, and adolescents with IDA refractory to oral iron therapy.
(Copyright © 2016 Elsevier Inc. All rights reserved.)
التعليقات: Comment in: J Pediatr. 2017 Jan;180:2. (PMID: 28010793)
Comment in: J Pediatr. 2017 May;184:241. (PMID: 28196681)
معلومات مُعتمدة: KL2 TR001103 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: heavy menstrual bleeding; inflammatory bowel disease; menorrhagia; nutritional
المشرفين على المادة: 0 (Ferric Compounds)
6897GXD6OE (ferric carboxymaltose)
69-79-4 (Maltose)
E1UOL152H7 (Iron)
تواريخ الأحداث: Date Created: 20161026 Date Completed: 20170615 Latest Revision: 20181013
رمز التحديث: 20221213
DOI: 10.1016/j.jpeds.2016.09.053
PMID: 27776750
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-6833
DOI:10.1016/j.jpeds.2016.09.053